79 | 0 | 15 |
下载次数 | 被引频次 | 阅读次数 |
目的 探究替格瑞洛联合阿司匹林对急性心肌梗死(AMI)患者疗效的影响。方法 选取2021年6月至2024年1月确诊的113例行经皮冠状动脉介入(PCI)的AMI患者为研究对象,随机分为对照组(n=57)和观察组(n=56),对照组术后采用氯吡格雷联合阿司匹林治疗,观察组术后采用替格瑞洛联合阿司匹林治疗。比较2组临床疗效、冠状动脉微循环情况、斑块稳定性、运动耐力、生活质量和不良反应发生情况。结果 治疗3个月后,观察组总有效率高于对照组(P<0.05),冠状动脉微循环情况优于对照组(P<0.05);2组冠状动脉斑块大小、厚度及血管中膜厚度均较治疗前降低(P<0.05),并且观察组低于对照组(P<0.05);2组运动耐力和生活质量均优于治疗前(P<0.05),并且观察组优于对照组(P<0.05);2组恶心呕吐、消化道出血、皮疹和腹泻不良反应总发生率比较差异无统计学意义(P > 0.05)。结论 替格瑞洛联合阿司匹林对AMI患者的疗效优于氯吡格雷联合阿司匹林,能够明显改善AMI患者的冠状动脉微循环,提高冠状动脉斑块稳定性,改善运动耐力和生活质量,安全性良好,值得临床推广。
Abstract:AIM To investigate the impacts of ticagrelor combined with aspirin on the efficacy in patients with acute myocardial infarction (AMI).METHODS A total of 113 AMI patients undergoing percutaneous coronary intervention (PCI) diagnosed in our hospital from June 2021 to January 2024 were taken as subjects.They were randomly assigned to the monitored group (n=56) and the control group (n=57).The control group was treated with aspirin combined with clopidogrel,while the monitored group was treated with aspirin combined with ticagrelor.Patients in2 groups were compared regarding efficacy,coronary microcirculation,plaque stability,exercise endurance,quality of life,and adverse reactions.RESULTS After 3 months of treatment,the total effective rate of the monitored group was greatly higher than that of the control group (P<0.05).Both groups were showed great improvement in coronary microcirculation,and the monitored group was greatly better than the control group (P<0.05).After treatment,the size,thickness,and intima-media thickness of coronary artery plaques were decreased in both groups,and the improvement in the monitored group was better than that in the control group (P<0.05).After treatment,the scores of exercise endurance and quality of life in both were groups greatly improved,and the monitored group had better scores than the control group(P<0.05).Total incidence of adverse reactions (such as nausea and vomiting,gastrointestinal bleeding,rash and diarrhea)was not statistically greatly different between 2 groups (P>0.05).CONCLUSION The combination of ticagrelor and aspirin has a great therapeutic effect on AMI patients,which can greatly improve coronary microcirculation,enhance plaque stability,improve exercise endurance and quality of life,with high safety and ideal efficacy,which is worthy of clinical application and promotion.
[1]吕莹,严自强,徐慧欣,等.替格瑞洛联合急诊经皮冠脉介入术治疗急性心肌梗死的效果及安全性[J].中国临床药学杂志, 2024,33(2):100.
[2] SEO J, LEE J, SHIN Y H, et al. Acute myocardial infarction after initially diagnosed with unprovoked venous thromboembolism:a case report[J]. World J Clin Cases, 2023, 11(30):7497.
[3]滕玉欢,杨鸥,王妍,等.不同时间窗对急性心肌梗死患者行冠状动脉介入临床疗效及其预后的影响[J].中国老年学杂志, 2023,43(14):3336.
[4]刘闯,闫佩佩,陈雅丽,等.急性心肌梗死患者NLR、LMR、PLR的表达及与PCI术后冠状动脉无复流的关系[J].中国循证心血管医学杂志, 2023, 15(5):616.
[5] EL-RABAT K A, HAMOUDA M A, EL-NAGAR A E, et al.Clinical and angiographic predictors of No-reflow phenomenon during primary percutaneous coronary intervention[J]. Benha J Appl Sci, 2021, 6(1):267.
[6]张莉莉.低剂量替格瑞洛在高出血风险ACS病人PCI术后抗血小板治疗中的有效性及安全性分析[J].中西医结合心脑血管病杂志, 2022, 20(13):2494.
[7]陈奇,刘洋,姬劲锐,等.西洛他唑联合氯吡格雷及阿司匹林对AMI病人PCI术后出血事件、凝血功能的影响[J].中西医结合心脑血管病杂志, 2022, 20(7):1279.
[8]潘砚鹏,陈文宽,王前,等.低剂量替格瑞洛联合阿司匹林双抗血小板治疗在冠状动脉旁路移植术后的应用[J].岭南心血管病杂志, 2022, 28(3):214.
[9]张敏州,丁邦晗,林谦.急性心肌梗死中医临床诊疗指南[J].中华中医药杂志, 2021, 36(7):4119.
[10]中华医学会心血管病学分会,中华心血管病杂志编辑委员会,《中国循环杂志》编辑委员会.急性心肌梗死诊断和治疗指南[J].中华心血管病杂志, 2001, 29(12):710.
[11]齐斌,张锐.替格瑞洛对急性冠脉综合征PCI术后TIMI血流及血小板功能的影响[J].国际心血管病杂志, 2017, 44(S1):169.
[12]丁贤彬,焦艳,毛德强,等. 2012-2018年重庆市急性心肌梗死发病死亡趋势分析[J].中国慢性病预防与控制, 2021, 29(1):33.
[13]陈红伟,苏淑红,王志方,等.老年急性心肌梗死患者主要不良心血管事件的影响因素分析及预测研究[J].中华老年心脑血管病杂志, 2022, 24(3):260.
[14] MARCUSCHAMER I, ZUSMAN O, IAKOBISHVILI Z, et al.Outcome of patients with prior coronary bypass surgery admitted with an acute coronary syndrome[J]. Heart, 2021, 107(22):1820.
[15]胡小红,朱剑,张芳,等.急性心肌梗死患者PCI术后早期被动运动模式构建及效果[J].中国老年学杂志, 2023, 43(14):3333.
[16] OSTOJIC Z, OSTOJIC A, BULUM J, et al. Safety and efficacy of dual antiplatelet therapy after percutaneous coronary interventions in patients with end-stage liver disease[J]. World J Cardiol,2021, 13(11):599.
[17]陈夏欢,刘梅林,张学斌.阿司匹林肠溶缓释片与阿司匹林肠溶片抗血小板聚集的药物经济学评价[J].中国药物经济学, 2021,16(10):5.
[18]王丽杰,韩丹宁.替格瑞洛治疗急性ST段抬高型心肌梗死患者的近期抗血小板疗效及不良反应发生情况[J].医学临床研究,2023, 40(5):699.
[19]李保强,黄斌,农玉梅.探讨尼可地尔联合替格瑞洛在PCI中安全性及对冠脉微循环障碍的影响[J].川北医学院学报, 2023,38(4):492.
[20]莫秀丽,陈文,曾梨.替格瑞洛联合阿司匹林对冠心病患者PCI术后微循环功能及凝血功能的影响[J].中国医学创新, 2020,17(17):64.
[21]刘广文,张富山,蔡俊.杏芎氯化钠注射液联合替格瑞洛治疗不稳定型心绞痛的临床研究[J].现代药物与临床, 2021, 36(2):260.
[22]王大宇,赵善隽,梁嘉永,等.替格瑞洛对急性冠脉综合征患者血清高敏C反应蛋白及血浆同型半胱氨酸水平的影响[J].心血管康复医学杂志, 2019, 28(1):72.
基本信息:
DOI:10.19577/j.1007-4406.2025.07.008
中图分类号:R542.22
引用信息:
[1]罗菊,沈青,顾立华.替格瑞洛联合阿司匹林对急性心肌梗死患者疗效的影响[J].中国临床药学杂志,2025,34(07):520-524.DOI:10.19577/j.1007-4406.2025.07.008.
基金信息: